$12.74
-3.26-20.37%
Last update: Nov 10, 7:07 PM
Mentari Therapeutics Inc
MTRINASDAQ
The average analyst price target for Mentari Therapeutics is $30, 130.8% above the current price. Of 2 analysts, 2 rate it Buy. The latest change came on Nov 10, 2026, when Jefferies initiated coverage of Mentari Therapeutics with a Buy rating and a $30 price target.
Price Target Range — 1 Quarters
Analyst Consensus — 2 Analysts
Rating Trend — Last 9 Months
